Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.
In: Clinical and translational medicine, Jg. 14 (2024-05-01), Heft 5, S. e1687
Online
academicJournal
Zugriff:
Objective: It has been observed that the prognosis of patients with HER2-positive metastatic breast cancer has improved significantly with HER2-targeted agents. However, there is still a lack of evidence regarding first-line anti-HER2 treatment options for patients who have received adjuvant and/or neoadjuvant trastuzumab for HER2-positive metastatic breast cancer. Besides, there are no reliable markers that can predict the efficacy of anti-HER2 treatment in these patients.
Methods: Patients who have received adjuvant and/or neoadjuvant trastuzumab for HER2-positive metastatic breast cancer were enrolled. Pyrotinib plus albumin-bound paclitaxel were used as first-line treatment. The primary endpoint was the objective response rate (ORR). The safety profile was also assessed. In order to explore predictive biomarkers using Olink technology, blood samples were collected dynamically.
Results: From December 2019 to August 2023, the first stage of the study involved 27 eligible patients. It has not yet reached the median PFS despite the median follow-up being 17.8 months. Efficacy evaluation showed that the ORR was 92.6%, and the DCR was 100%. Adverse events of grade 3 or higher included diarrhoea (29.6%), leukopenia (11.1%), neutropenia (25.9%), oral mucositis (3.7%), and hand-foot syndrome (3.7%). Toll-like receptor 3 (TLR3) and Proto-oncogene tyrosine-protein kinase receptor (RET) were proteins with significant relevance to PFS in these patients.
Conclusions: This study demonstrates that pyrotinib plus albumin-bound paclitaxel as a first-line treatment regimen shows good efficacy and manageable safety for patients who have received adjuvant and/or neoadjuvant trastuzumab for HER2-positive metastatic breast cancer. Besides, a significant association was identified between the expression levels of TLR3 and RET and the PFS in patients.
(© 2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.)
| Titel: |
Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.
|
|---|---|
| Autor/in / Beteiligte Person: | Man, X ; Huang, J ; Sun, S ; Zhou, D ; Zhang, B ; Fang, S ; Zheng, F ; Li, C ; Wang, X ; Huang, W ; Wang, L ; He, Q ; Fu, H ; Zhang, Y ; Liu, C ; Dong, L ; Zhao, X ; Xu, L ; Sun, X ; Fan, B ; Song, L ; Zhou, Z ; Yu, J ; Li, H |
| Link: | |
| Zeitschrift: | Clinical and translational medicine, Jg. 14 (2024-05-01), Heft 5, S. e1687 |
| Veröffentlichung: | 2020- : [Hoboken, NJ] : Wiley ; <i>Original Publication</i>: Heidelberg : Springer-Verlag, 2024 |
| Medientyp: | academicJournal |
| ISSN: | 2001-1326 (electronic) |
| DOI: | 10.1002/ctm2.1687 |
| Schlagwort: |
|
| Sonstiges: |
|